Here at IPstreet.com, we want to change the story. In fact, we want to help inventors get beyond (1) conceptualization and through the important stages of (2) gestation, (3) early incubation, and (4) late incubation. To help you and your inventions, we also need to help those who support the invention process: patent attorneys, IP portfolio managers, senior executives, and investors. We believe you are the engine that drives economic development, and the supporting cast fuels the innovation process. In this section, you will learn more about how your inventions can be protected and commercialized. Whether you are a new inventor or are a patenting guru, we hope you will find our resources relevant and practical. Our content is developed by subject matter experts in business and IP law; an uncommon union of PhDs and JDs to help you make sense of the IP landscape in the development of your invention, and its ultimate commercialization.

Before you decide to visit a patent attorney, you should educate yourself. Whether you are a newbie or a guru, our tools can help you know more so you can be better prepared. You can learn about patents related to your invention for just $99. Compare that to the average $250/hour your lawyer will charge you.

During development, IP Street was very fortunate and grateful to have early partners that signed on to use our tools, often in beta form. Through timely and constructive feedback, our partners were instrumental in helping us develop features that evolved from "interesting and cool" to "nice to have" to "got to have". Below is a sampling of some of the enterprise partners who understood our vision very early on. They became annual subscribers and were afforded the benefits of having direct access to our development team, enabling us to design more relevant tools and allowing them to enjoy influence in design priorities. They include: Alibaba, Amazon, Lee & Hayes, PAML, T-Mobile. Thank you to all of our enterprise partners.

Here are five common factors that often determine the worth of an invention. (1) Importance of a Patent: For breakthrough patents, a.k.a. foundational patents, the patents are so innovative that they give the owner a complete monopoly over an entire industry and are extremely valuable, often worth billions of dollars. Although most patents never reach these heady heights they are nevertheless valuable in that they can force a competitor to start innovating to keep pace with new and improved technologies and products in the market. Incremental patents, which make only small advances over existing products, are usually the least valuable though this may not be always so. A question that is often asked in relation to endeavoring to put a price on a patent is 'How much would my competitors pay to use my protected product or process?' (2) The Market: Market size, the number of products that are likely to be made and the cost of each product also have a significant bearing on the value of a patent. What sort of sales can the patent be expected to support, and for how long? A good example of an article which has significant market presence is the ubiquitous Intel chip that is reported to have a value estimated in the billions of dollars. (3) The Patent Term: Patents have a maximum life of 20 years and, therefore, a 20-year potential monopoly. Patents that are just beginning their life and which have longer to run on the their potential monopoly position understandably will have more value. It is rare that a patent nearing the end of its term will cause a great threat to its competitors. It is almost certain that they will have devised technologies or products of their own by then that will not interfere with the patent owners monopoly position. In addition, one has to take into consideration the potential business life of a patent, i.e., the duration, which a patent is likely to be economically useful, if other subsequent patents are providing better alternatives to it. (4) Amount of Prior Art: The number of cited documents or patented products populating an area of innovation also has an effect on the value of a patent. Generally, if the particular product is one of many products of a similar type then the consumers' options de-value the patent of interest, yielding a relatively smaller premium than, for example, a stand alone patent with a captured customer base and no adjacent competition. (5) Patent Significance: Every patent has its own significance in a particular area and will usually form part of an overall IP strategy either to maximize its earning potential or to allow other patents to maximize theirs. Examples of such patents are those that are used to block other key players from gaining a foothold in a market. Yet other examples are those patents that are additional to an original patent and rely on the protected matter in the original patent to successfully operate. It is not uncommon for drug companies or telecom companies to take out further patents protecting a strong first generation of patents, thus securing a big chunk of a market and the ability to negotiate licenses and royalties from the protected, but much desired technology.

Lee is IP Street's CEO. Art Coffey, a business strategist who took RLH public on the NYSE as its CFO, best known for his leadership as the President and Chief Executive Officer of Red Lion Hotels Corporation from 2003 to 2008, is COO & CFO. Tammy Krieger, Director of Product Management, was formerly in a leading role with Microsoft's patent group and brings expertise in data management, patent analysis and process optimization. John Vogel, Vice President of Engineering, leads the software development team, formerly co-founded and developed Saas companies such as Four Creeks. The team is backed by a board of directors that include Stacey Cowles (Cowles Company), Dennis Hopton (York Trade Limited of Hong Kong), George Nethercutt (former U.S. Representative), and Lee and Coffey. IP Street's advisory board includes Roger Cheng (Alibaba), Scott Hayden (Amazon), Shawn Clark (Microsoft), Dan Crouse (Lee & Hayes), John Murphy (T-Mobile), and Joseph Schappert, MD (PAML). The company is privately funded.